258 related articles for article (PubMed ID: 30005007)
1. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
[TBL] [Abstract][Full Text] [Related]
3. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.
Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M
PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036
[TBL] [Abstract][Full Text] [Related]
4. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
6. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
Jessen Krut J; Mellberg T; Price RW; Hagberg L; Fuchs D; Rosengren L; Nilsson S; Zetterberg H; Gisslén M
PLoS One; 2014; 9(2):e88591. PubMed ID: 24523921
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.
Hermansson L; Yilmaz A; Axelsson M; Blennow K; Fuchs D; Hagberg L; Lycke J; Zetterberg H; Gisslén M
J Neuroinflammation; 2019 Jan; 16(1):16. PubMed ID: 30678707
[TBL] [Abstract][Full Text] [Related]
9. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
[TBL] [Abstract][Full Text] [Related]
10. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.
McGuire JL; Gill AJ; Douglas SD; Kolson DL;
J Neurovirol; 2015 Aug; 21(4):439-48. PubMed ID: 25776526
[TBL] [Abstract][Full Text] [Related]
11. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.
Gisslen M; Hagberg L; Brew BJ; Cinque P; Price RW; Rosengren L
J Infect Dis; 2007 Jun; 195(12):1774-8. PubMed ID: 17492593
[TBL] [Abstract][Full Text] [Related]
12. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients.
Hagberg L; Fuchs D; Rosengren L; Gisslén M
J Neuroimmunol; 2000 Jan; 102(1):51-5. PubMed ID: 10626666
[TBL] [Abstract][Full Text] [Related]
14. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
[TBL] [Abstract][Full Text] [Related]
15. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.
Gisslén M; Price RW; Andreasson U; Norgren N; Nilsson S; Hagberg L; Fuchs D; Spudich S; Blennow K; Zetterberg H
EBioMedicine; 2016 Jan; 3():135-140. PubMed ID: 26870824
[TBL] [Abstract][Full Text] [Related]
16. CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
Abdulle S; Mellgren A; Brew BJ; Cinque P; Hagberg L; Price RW; Rosengren L; Gisslén M
J Neurol; 2007 Aug; 254(8):1026-32. PubMed ID: 17420923
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
18. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.
Abdulle S; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
AIDS; 2002 Nov; 16(16):2145-9. PubMed ID: 12409735
[TBL] [Abstract][Full Text] [Related]
19. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
[TBL] [Abstract][Full Text] [Related]
20. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study.
Alagaratnam J; De Francesco D; Zetterberg H; Heslegrave A; Toombs J; Kootstra NA; Underwood J; Gisslen M; Reiss P; Fidler S; Sabin CA; Winston A
J Neurovirol; 2022 Feb; 28(1):54-63. PubMed ID: 34874540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
